Furochromene Estrogen Modulators Tissue-Specific Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current estrogen replacement therapies and hormone replacement therapies for menopausal symptoms and osteoporosis often come with adverse side effects such as breast cancer and endometrial carcinoma, and selective estrogen receptor modulators like zitazonium and raloxifene can cause endometrial carcinoma and hot flashes, limiting their long-term application.
Innovation Solution
A compound represented by formula I, a prodrug, and its pharmaceutically active metabolite, along with stereoisomers and pharmaceutically acceptable salts, are developed for use in a medicament to treat and prevent estrogen-related diseases, administered orally or parenterally, potentially combined with other agents like organic diphosphonates or cathepsin K inhibitors, to provide estrogen-like actions with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If estrogen replacement therapy is used to treat menopausal symptoms and osteoporosis, then the incidence of osteoporotic fracture and coronary heart disease is significantly reduced, but the risk of breast cancer and endometrial carcinoma increases
Solution Approach 1:
The compound is designed to exhibit tissue-specific estrogenic effects: it acts as an estrogen agonist on bone and cardiovascular systems while functioning as an antagonist on uterine and breast tissues. This differential tissue response is achieved through molecular structure optimization that selectively interacts with estrogen receptors in different organs, allowing beneficial effects in target tissues while blocking harmful effects in sensitive tissues.
Solution Approach 2:
The invention modifies the chemical structure parameters of traditional estrogen compounds by introducing specific substituents at defined positions in the molecular framework. These structural parameter changes alter the compound's binding affinity and conformational effects on estrogen receptors, transforming it from a full agonist (like natural estrogen) to a selective modulator with tissue-dependent activity patterns.
2Object-affected harmful factors
If hormone replacement therapy involving joint action of estrogen and progestogen is used, then adverse side effects of estrogen are overcome, but long-term use increases the incidence of breast cancer
Solution Approach 1:
The compound provides protective effects in specific tissues (bone and cardiovascular system) while simultaneously exerting anti-estrogenic effects in breast tissue. This dual functionality eliminates the need for progestogen addition, as the compound itself prevents estrogen-induced breast cancer risk while maintaining beneficial effects elsewhere in the body.
Solution Approach 2:
The invention extracts and isolates the beneficial estrogenic effects (on bone and cardiovascular system) from the harmful effects (on breast and uterus) by designing a molecule that selectively activates or blocks estrogen receptors in different tissues. This separation allows therapeutic use without the need for progestogen counterbalance.
3Reliability
If selective estrogen receptor modulators like raloxifene are used, then estrogen-like actions on bone and cardiovascular systems are achieved, but adverse side effects such as endometrial carcinoma and hot flashes occur
Solution Approach 1:
The compound is engineered to produce tissue-specific responses: it acts as an agonist on bone and cardiovascular tissues while functioning as an antagonist on uterine tissue. This selective action pattern differs from raloxifene, which can have unpredictable effects on the endometrium, providing a more reliable safety profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively treats and prevents estrogen-related diseases such as osteoporosis, breast cancer, and endometrial carcinoma with reduced side effects, offering a safer alternative to existing therapies by selectively acting on bone and cardiovascular systems while minimizing uterine and breast tissue effects.
Implementation Method 1
Due to their spatial structure similarity with estrogen, furochromene derivatives can simulate estrogen, bind to estrogen receptors in organisms, and thus exert physiological actions
Data Source
AI summary
Disclosed are furo[3,2-g]chromene derivatives represented by formula (I), stereoisomers, pharmaceutically acceptable salts, and pharmaceutical compositions thereof, as well as uses thereof as estrogen receptor modulators.